In a press statement released Monday, biotech firm Impax Laboratories (NASDAQ:IPXL) announced that the FDA has given the company a response to its New Drug Application for Rytary, the company's aspiring sustained-release Parkinson's Disease treatment, asking for a reinspection of Impax's development plant in Hayward, Calif. According to Impax, the FDA previously issued a warning letter about the facility back in 2011.

Impax CEO and president Larry Hsu was quoted in the statement as saying, "We will work with the FDA on the appropriate next steps for the RYTARY application ... We remain committed to resolving the warning letter and bringing this new treatment option to patients who are suffering from Parkinson's disease."

Should Rytary be approved, estimates have pegged peak sales of the drug between $200 million and $300 million annually. Impax will market and sell the drug in the U.S. and Taiwan, while GlaxoSmithKline (NYSE:GSK) will handle such duties in other international regions.


Dan Carroll has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.